Loss of endogenous TGF-β effect induces mouse hepatoma malignancy by correlation with cyclooxygenase-2 and VEGF

Hepatology Research

Volumn 26, Issue 4, 2003, Pages 302-310

  Kim, Kye Young ^a   Lee, June Woo ^a   Ahn, Byeong Woo ^b   Ryu, Pan Dong ^c   Nam, Myeong Jin ^a  

^a Korea National Institute of Health   (South Korea)

^b Korea Food and Drug Administration   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

Celecoxib; Cyclooxygenase (COX); Hepatoma; Transforming growth factor (TGF ); Vascular endothelial growth factor (VEGF)

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; PROTEIN BCL 2; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CARCINOGENICITY; CELL GROWTH; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HEPATOMA CELL; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN DOMAIN; REGULATORY MECHANISM;

EID: 0141503959     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(03)00155-4     Document Type: Article

References (42)

1. Sheng H, Shao J, O'Mahony CA, et al. Transformation of intestinal epithelial cells by chronic TGF-β1 treatment results in downregulation of the type II TGF-β receptor and induction of cyclooxygenase-2. Oncogene 1999;18:855-67.
2. Selvakumaran M, Lin HK, Sjin RT, Reed JC, Lieberman DA, Hoffman B. The novel primary response gene Myd118 and the protooncogene myb, myc and bcl-2 modulate transforming growth factor β1-induced apoptosis of myeloid leukemia cells. Mol Cell Biol 1994;14:2352-60.
3. Rotello RJ, Liebermann RC, Purchio AF, Gerschenson LE. Coordinated regulation of apoptosis and cell proliferation by transforming growth factor β1 in cultured uterine epithelial cells. Proc Natl Acad Sci USA 1991;88:3412-5.
4. Wang CY, Eshleman JR, Willson JKV, Markowitz S. Both transforming growth factor β and substrate release is inducers of apoptosis in a human colon adenoma cell line. Cancer Res 1995;55:5101-5.
5. Fukuda K, Kojiro M, Chiu JF. Induction of apoptosis by transforming growth factor β1 in the rat hepatoma cell line McA-RH7777: a possible association with tissue transglutaminase expression. Hepatology 1993;18:945-52.
6. Lin HY, Wang X, Ng-Eaton E, Weinberg RA, Lodish HF. Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell 1992;68:775-85.
7. Wieser R, Attisano L, Wrana JF, Massague J. Signaling activity of transforming growth factor type II receptors lacking specific domains in the cytoplasmic region. Mol Cell Biol 1993;13:7239-47.
8. Haddow S, Fowlis DJ, Parkinson K, Akhurst RJ, Balmain A. Loss of growth control by TGF-beta occurs at a late stage of mouse skin carcinogenesis and is independent of ras gene activation. Oncogene 1991;6:1465-70.
9. Beauchamp RD, Lyons RM, Yang EY, Coffey RJJ, Moses HL. Expression of and response to growth regulatory peptides by two human pancreatic carcinoma cell lines. Pancreas 1990;5:369-80.
10. Sun L, Wu G, Willson JK, et al. Expression of transforming growth factor β type II receptor leads to reduce malignancy in human breast cancer MCF-7 cells. J Biol Chem 1994;269:26445-9.
11. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995;68:1336-8.
12. Smith WL, Garavito RM, Dewitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271:33157-60.
13. Williams CS, DuBois RN. Prostaglandin endoperoxide synthase: why two isoforms. Am J Physiol 1996;270:G393-400.
14. Bronestein J, Bull A. The correlation between 13-hydroxyoctadecadienoate dehydrogenase (13-HODE dehydrogenase) and intestinal cell differentiation. Prostaglandins 1993;46:387-95.
15. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
16. DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996;110:1259-62.
17. Li J, Simmons DL, Tsang BK. Regulation of hen granulosa cell prostaglandin production by transforming growth factors during follicular development: involvement of cyclooxygenase II. Endocrinology 1996;137:2522-9.
18. Sheng H, Shao J, Hooton EB, Tsujii M, DuBois RN, Beauchamp RD. Cyclooxygenase-2 induction and transforming growth factor (TGF -β growth inhibition in rat intestinal epithelial cells. Cell Growth Differ 1997;8:463-70.
19. Gilbert RS, Reddy ST, Kujubu DA, Xie W, Luner S, Herschman HR. Transforming growth factor betal augments mitogen-induced prostaglandin synthesis and expression of the TIS10/prostaglamdin synthase 2 gene both in Swiss 3T3 cells and murine embryo fibroblasts. J Cell Physiol 1994;159:67-75.
20. Reddy ST, Gilbert RS, Xie W, Luner S, Herschman HR. TGF-β1 inhibits both endotoxin-induced prostaglandin synthesis and expression of the TIS10/prostaglandin synthase-2 gene in murine macrophages. J Leukocyte Biol 1994;55:192-200.
21. Won J, Kim H, Park EJ, Hong Y, Kim SJ, Yun Y. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor β receptor therapy. Cancer Res 1999;59:1273-7.
22. Kim KY, Jeong SY, Won J, Ryu PD, Nam MJ. Induction of angiogenesis by expression of soluble type II transforming growth factor β receptor in mouse hepatoma. J Biol Chem 2001;276:38781-6.
23. Tricoli JV, Gumerlock PH, Yao JL, Chi SG, D'Souza SA, Nestok BR, deVere White RW. Alterations of the retinoblastoma gene in human prostate adenocarcinoma. Genes Chromosomes Cancer 1996;15:108-14.
24. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000;60:1306-11.
25. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 1980;284:555-6.
26. Gavriey Y, Sherman Y, Bensasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
27. Matsuzaki K, Date M, Furukawa F, Tahashi Y, Matsushita M, Sakatani K, Yamashiki N, Seki T, Saito H, Nishizawa M, Fujisawa J, Inoue K. Autocrine stimulatory mechanism by transforming growth factor β in human hepatocellular carcinoma. Cancer Res 2000;60:1394-402.
28. Sheng H, Shao J, Kirkland SM, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254-9.
29. Shao J, Sheng H, Aramandla R, et al. Coordinate regulation of cyclooxygenase-2 and TGF-β1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis 1999;20:185-91.
30. Pertovaara L, Kaipainen A, Mustonen T, Orpana A, Ferrara N, Saksela O, Alitalo K. Vascular endothelial growth factor in induced in response to transforming growth factor β in fibroblastic and epithelial cells. J Biol Chem 1994;269:6271-4.
31. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor. Cancer Res 2000;60:2101-3.
32. Capocasale RJ, Lamb RJ, Vonderheid EC, Fox FE, Rook AH, Nowell PC, Moore JS. Reduced surface expression of transforming growth factor β receptor type II in mitogen-activated T cells from Sezary patients. Proc Natl Acad Sci USA 1995;92:5501-5.
33. Kadin ME, Cavaille-Coll MW, Gertz R, Massague J, Cheifetz S, George D. Loss of receptors for transforming growth factor β in human T-cell malignancies. Proc Natl Acad Sci USA 1994;91:6002-6.
34. Wieser R, Attisano L, Wrana JF, Massague J. Signal activity of transforming growth factor type II receptors lacking specific domains in the cytoplasmic region. Mol Cell Biol 1993;13:7239-47.
35. Lin HY, Moustakas A, Knaus P, Wells RG, Henis YI, Lodish HF. The soluble cytoplasmic domain of type II transforming growth factor (TGF)-β receptor. A heterogeneously glycosylated protein with affinity and selectivity for TGF-β ligands. J Biol Chem 1995;270:2747-54.
36. Guo Y, Kyprianou N. Restoration of transforming growth factor β signaling pathway in human prostater cancer cells suppresses tumorigenicity via induction of caspase-1-mediated apoptosis. Cancer Res 1999;59:1366-71.
37. Meade EA, McIntyre TM, Zimmerman GA, Prescott SM. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem 1999;274:8328-34.
38. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, Ogier-Denis E. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 1997;277:27613-21.
39. Vogiagis D, Brown W, Glare EM, O'Brien PE. Rat colorectal tumours treated with a range of non-steroidal anti-inflammatory drugs show altered cyclooxygenase-2 and cyclooxygenase-1 splice variant mRNA expression levels. Carcinogenesis 2001;22:869-74.
40. Gallo O, Franchi A, Magnelli L, Sardi I, Vannacci A, Boddi V, Chiarugi V, Masini E. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001;3:53-61,
41. Ayalasomayajula SP, Kompella UB. Celecoxib, a selective cyclooxygenase-2 inhibitor, inhibits retinal vascular endothelial growth factor expression and vascular leakage in a streptozotocin-induced diabetic rat model. Eur J Pharmacol 2003;458:283-9.
42. Tsujii M, Sunao K, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells oncreases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336-40.